Hepatocellular Carcinoma: Patients With Increasing Alpha-Fetoprotein But No Mass on Ultrasound

Josep M. Llovet

doi:10.1016/s1542-3565(05)00864-5

Related publications

Article2020

Impact of baseline hepatitis B viremia and management on outcomes in advanced hepatocellular carcinoma and elevated alpha-fetoprotein: outcomes from REACH-2

Peter R. Galle, Masatoshi Kudo, Josep M. Llovet, Richard S. Finn, Mark Karwal, Denis Pezet, Tae‐You Kim, Tsai‐Sheng Yang, Vittorina Zagonel, Jiří Tomášek, Jean-Marc Phélip, Yann Touchefeu, Su‐Jin Koh, Guido Stirnimann, Chunxiao Wang, Kenyon D. Ogburn, Paolo Abada, Ryan C. Widau, Andrew X. Zhu

Journal of Hepatology

Article2009

CLINICAL ADVANCES IN LIVER, PANCREAS, AND BILIARY TRACT -Fetoprotein, Des- Carboxyprothrombin, and Lectin-Bound -Fetoprotein in Early Hepatocellular Carcinoma

Jorge A. Marrero, Ziding Feng, Yinghui Wang, Mindie H. Nguyen, Alex S. Befeler, Lewis R. Roberts, K. Rajender Reddy, Denise M. Harnois, Josep M. Llovet, Daniel P. Normolle, Jackie Dalhgren, David Chia, Anna S. Lok, Paul D. Wagner, Sudhir Srivastava, Myron Schwartz

Letter2019

Ramucirumab in advanced hepatocellular carcinoma in REACH-2: the true value of α-fetoprotein

Andrew X. Zhu, Richard S. Finn, Peter R. Galle, Josep M. Llovet, Masatoshi Kudo

The Lancet Oncology

Article2004

Focus on hepatocellular carcinoma

Jordi Bruix, Loreto Boix, María Sala, Josep M. Llovet

Cancer Cell

Article2001

Chemoembolization improves survival in patients with unresectable hepatocellular carcinoma (HCC)

Josep M. Llovet, María Isabel Real, R. Vilana, Ramón Planas, S. Coll, John J. Aponte, Carmen Ayuso, María Sala, Jordi Muchart, R. Costa, J Rodés, Jordi Bruix